Stock listing
BOATS:PYPD PolyPid Ltd. Stock
US listing (BOATS) of PolyPid Ltd. · home listing NASDAQ:PYPD
Follow PolyPid Ltd. into a list and get an email when it puts out news.
Home listing price · NASDAQ:PYPD
$6.12 USD -0.44 (-6.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:PYPD
- Day range
- $6.09 – $6.76 USDNov 20, 2026
- Volume
- 448,947 sharesNov 20, 2026
- Market cap
- $124.3M USDAt the close on Nov 20, 2026 · price × 20.31M shares outstanding
- 52-week range
- $3.50 – $7.14 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $805,215 USDMedian day 113,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PYPD · Home | $6.12 USD | -0.44 (-6.7%) | 448,947 | $6.55 | $6.76 | $6.09 | $6.56 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PYPD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.12 | -0.44 | -6.7% | $6.55 | $6.76 | $6.09 | 448,947 | |
| $6.56 | +0.02 | +0.3% | $6.60 | $6.80 | $6.46 | 303,794 | |
| $6.54 | +0.39 | +6.3% | $6.21 | $6.57 | $6.12 | 761,469 | |
| $6.15 | -0.11 | -1.8% | $6.23 | $6.25 | $6.03 | 211,749 | |
| $6.26 | -0.14 | -2.2% | $6.58 | $6.58 | $6.03 | 193,125 | |
| $6.40 | -0.20 | -3.0% | $6.968 | $6.968 | $6.33 | 188,305 | |
| $6.60 | +0.29 | +4.6% | $6.50 | $7.14 | $6.18 | 424,498 | |
| $6.31 | +0.07 | +1.1% | $6.24 | $6.35 | $5.90 | 151,914 | |
| $6.24 | +0.10 | +1.6% | $6.17 | $6.48 | $6.055 | 263,284 | |
| $6.14 | +0.47 | +8.3% | $5.71 | $6.14 | $5.52 | 183,944 | |
| $5.67 | -0.15 | -2.6% | $5.82 | $5.93 | $5.36 | 241,864 | |
| $5.82 | +0.36 | +6.6% | $5.56 | $5.89 | $5.56 | 170,245 | |
| $5.46 | +0.04 | +0.7% | $5.74 | $5.74 | $5.32 | 100,437 | |
| $5.42 | +0.03 | +0.6% | $5.548 | $5.69 | $5.27 | 205,692 | |
| $5.39 | -0.20 | -3.6% | $5.54 | $5.59 | $5.39 | 100,724 | |
| $5.59 | -0.19 | -3.3% | $5.84 | $5.84 | $5.55 | 93,269 | |
| $5.78 | +0.01 | +0.2% | $5.77 | $5.80 | $5.54 | 134,846 | |
| $5.77 | +0.48 | +9.1% | $5.34 | $5.79 | $5.34 | 228,926 | |
| $5.29 | +0.04 | +0.8% | $5.25 | $5.365 | $5.17 | 93,977 | |
| $5.25 | +0.12 | +2.3% | $5.14 | $5.25 | $5.11 | 103,800 | |
| $5.13 | +0.06 | +1.2% | $5.02 | $5.19 | $4.92 | 155,300 | |
| $5.07 | -0.08 | -1.6% | $5.19 | $5.21 | $5.00 | 137,100 | |
| $5.15 | +0.27 | +5.5% | $4.88 | $5.17 | $4.77 | 109,500 | |
| $4.88 | +0.16 | +3.4% | $5.00 | $5.091 | $4.77 | 110,700 | |
| $4.72 | -0.18 | -3.7% | $4.82 | $4.90 | $4.72 | 150,500 | |
| $4.90 | +0.07 | +1.4% | $4.70 | $4.97 | $4.61 | 120,600 | |
| $4.83 | -0.05 | -1.0% | $4.89 | $4.95 | $4.75 | 133,100 | |
| $4.88 | -0.14 | -2.8% | $5.04 | $5.08 | $4.80 | 93,400 | |
| $5.02 | -0.05 | -1.0% | $5.07 | $5.10 | $5.00 | 77,600 | |
| $5.07 | +0.17 | +3.5% | $4.91 | $5.16 | $4.90 | 60,000 | |
| $4.90 | -0.05 | -1.0% | $4.92 | $4.99 | $4.75 | 88,900 | |
| $4.95 | -0.18 | -3.5% | $5.11 | $5.19 | $4.90 | 113,400 | |
| $5.13 | -0.07 | -1.3% | $5.22 | $5.24 | $5.05 | 86,600 | |
| $5.20 | +0.01 | +0.2% | $5.28 | $5.33 | $5.03 | 102,000 | |
| $5.19 | -0.18 | -3.4% | $5.49 | $5.55 | $5.06 | 167,700 | |
| $5.37 | +0.10 | +1.9% | $5.30 | $5.47 | $5.28 | 118,800 | |
| $5.27 | -0.02 | -0.4% | $5.27 | $5.355 | $5.16 | 47,400 | |
| $5.29 | -0.02 | -0.4% | $5.40 | $5.40 | $5.23 | 66,000 | |
| $5.31 | +0.09 | +1.7% | $5.22 | $5.43 | $5.186 | 75,800 | |
| $5.22 | -0.14 | -2.6% | $5.33 | $5.45 | $5.22 | 44,800 | |
| $5.36 | +0.09 | +1.7% | $5.27 | $5.365 | $5.19 | 60,200 | |
| $5.27 | -0.18 | -3.3% | $5.43 | $5.43 | $5.10 | 69,100 | |
| $5.45 | +0.28 | +5.4% | $5.19 | $5.464 | $5.19 | 127,000 | |
| $5.17 | -0.04 | -0.8% | $5.22 | $5.345 | $5.12 | 40,600 | |
| $5.21 | +0.18 | +3.6% | $5.06 | $5.30 | $5.06 | 66,400 | |
| $5.03 | -0.18 | -3.5% | $5.25 | $5.34 | $5.03 | 105,000 | |
| $5.21 | +0.05 | +1.0% | $5.15 | $5.22 | $5.00 | 76,500 | |
| $5.16 | -0.17 | -3.2% | $5.32 | $5.33 | $5.03 | 81,700 | |
| $5.33 | +0.18 | +3.5% | $5.18 | $5.35 | $5.14 | 180,700 | |
| $5.15 | -0.01 | -0.2% | $5.20 | $5.24 | $5.04 | 99,300 | |
| $5.16 | -0.04 | -0.8% | $5.20 | $5.382 | $5.13 | 69,600 | |
| $5.20 | -0.13 | -2.4% | $5.22 | $5.39 | $5.16 | 141,600 | |
| $5.33 | -0.06 | -1.1% | $5.39 | $5.565 | $5.235 | 87,300 | |
| $5.39 | +0.12 | +2.3% | $5.30 | $5.44 | $5.21 | 73,100 | |
| $5.27 | -0.03 | -0.6% | $5.36 | $5.36 | $5.20 | 65,500 | |
| $5.30 | -0.03 | -0.6% | $5.32 | $5.35 | $5.16 | 143,800 | |
| $5.33 | +0.19 | +3.7% | $5.17 | $5.55 | $5.14 | 242,100 | |
| $5.14 | +0.07 | +1.4% | $5.08 | $5.15 | $5.00 | 55,600 | |
| $5.07 | -0.05 | -1.0% | $5.13 | $5.145 | $4.985 | 63,500 | |
| $5.12 | +0.01 | +0.2% | $5.18 | $5.24 | $5.01 | 78,100 | |
| $5.11 | +0.01 | +0.2% | $5.07 | $5.23 | $4.96 | 149,300 | |
| $5.10 | +0.115 | +2.3% | $5.04 | $5.19 | $5.015 | 139,606 | |
| $4.985 | -0.115 | -2.3% | $5.12 | $5.18 | $4.97 | 124,422 | |
| $5.10 | +0.02 | +0.4% | $5.10 | $5.205 | $4.99 | 169,100 | |
| $5.08 | +0.07 | +1.4% | $5.04 | $5.12 | $4.96 | 129,400 |
Splits
1 split · NASDAQ:PYPD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- BOATS:PYPD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Latest earnings call · Nov 11, 2026
PolyPid (NASDAQ:PYPD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 22 slides
Latest news
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Nov 11, 2026
Closed $6.60 (+4.6%) on Nov 11, 2026
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
Oct 29, 2026
Closed $5.59 (-3.3%) on Oct 29, 2026
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
Oct 28, 2026
Closed $5.78 (+0.2%) on Oct 28, 2026
PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026
Oct 21, 2026
Closed $5.07 (-1.6%) on Oct 21, 2026
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
Oct 15, 2026
Closed $4.90 (+1.4%) on Oct 15, 2026
European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀
Oct 1, 2026
Closed $5.37 (+1.9%) on Oct 1, 2026
PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities
Oct 1, 2026
Closed $5.37 (+1.9%) on Oct 1, 2026
PolyPid Announces Participation in Upcoming Fall Investor Conferences
Sep 15, 2026
Closed $5.16 (-3.2%) on Sep 15, 2026
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Aug 12, 2026
Closed $4.84 (+2.3%) on Aug 12, 2026
PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD)
Jul 31, 2026
Closed $4.29 (-1.8%) on Jul 31, 2026
PolyPid Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 145 in all · newest Nov 11, 2026 · oldest 2020
- Calls
- 23 calls with a replay · 23 with a transcript · latest Nov 11, 2026
- Decks
- 7 decks · latest August 2026
Where PolyPid Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PYPD · Home listing | NASDAQ | United States | USD |
| BOATS:PYPD · This page | BOATS | United States | USD |
| Frankfurt:2PV | Frankfurt | Germany | EUR |
Cash and shares
Jun 30, 2026 · PolyPid — Investor Presentation (August 2026)
- Shares outstanding
- 20.3 million
Valuation
Price/book 23.1× against a median of 3.2×: the highest of 11 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $119.3M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 23.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 0.93
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Yoda Pharmaceuticals Inc. · TPEX:7829 | US$127.1M | US$94.37M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| IntoCell, Inc. · KRX:287840 | US$126.6M | US$108.8M | n/a | 45.9× | n/a | 8.7× | −295.9% | 0.0× | n/a |
| UnicoCell Biomed Co., Ltd. · TWSE:6794 | US$126.3M | US$106.5M | n/a | 117× | n/a | 5.1× | −381.5% | 0.1× | n/a |
| MacroGenics, Inc. · NASDAQ:MGNX | US$125.3M | −US$127.6M | n/a | −0.9× | n/a | 5.0× | −34.6% | 1.4× | 0.83 |
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Biomm SA · BMFBOVESPA:BIOM3 | US$122.6M | US$136.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.23M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.66M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| Median of the others | US$123.8M | US$81.80M | 18.4× | 40.1× | 12.3× | 3.2× | −214.8% | 0.1× | 1.22 |
Forecasts
4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.50 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.10 · 3 analysts
- Revenue, year to Dec 2026
- 21.05M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Dikla Czaczkes Akselbrad | Chief Executive Officer |
| Ori Warshavsky | PolyPid Investor Relations and Media Contacts |
Board
| Director | Role |
|---|---|
| Brooke Story | Chairman of the Board |
| Jacob Harel | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| PolyPid (NASDAQ:PYPD) Q3 2026 Earnings Call | Wed, Nov 11, 2026 · 8:30 AM ET | Replay |
| PolyPid (NASDAQ:PYPD) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 8:30 AM ET | Replay |
| PolyPid (NASDAQ:PYPD) Q1 2026 Earnings Call | Wed, May 13, 2026 · 8:30 AM ET | Replay |
| PolyPid (NASDAQ:PYPD) Q4 2025 Earnings Call | Wed, Feb 11, 2026 · 8:30 AM ET | Replay |
| PolyPid (NASDAQ:PYPD) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 8:30 AM ET | Replay |
| PolyPid (NASDAQ:PYPD) Q2 2025 Earnings Call | Wed, Aug 13, 2025 · 8:30 AM ET | Replay |
| PolyPid (NASDAQ:PYPD) Q1 2025 Earnings Call | Wed, May 14, 2025 · 8:30 AM ET | Replay |
| PolyPid (NASDAQ:PYPD) Q4 2024 Earnings Call | Wed, Feb 12, 2025 · 8:30 AM ET | Replay |
| PolyPid (NASDAQ:PYPD) Q2 2024 Earnings Call | Wed, Aug 14, 2024 · 8:30 AM ET | Replay |
| PolyPid (NASDAQ:PYPD) Q1 2024 Earnings Call | Wed, May 08, 2024 · 8:30 AM ET | Replay |
All 23 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 11, 2026 · Before open | +4.6% |
| Q2 2026 | Aug 12, 2026 · Before open | +2.3% |
| Q1 2026 | May 13, 2026 · Before open | −7.5% |
| Q4 2025 | Feb 11, 2026 · Before open | −1.3% |
| Q3 2025 | Nov 12, 2025 · Before open | −0.3% |
| Q2 2025 | Aug 13, 2025 · Before open | +2.0% |
| Q1 2025 | May 14, 2025 · Before open | +7.0% |
| Q4 2024 | Feb 12, 2025 · Before open | +3.0% |
| Q3 2024 | Nov 13, 2024 · Before open | −2.9% |
| Q2 2024 | Aug 14, 2024 · Before open | −2.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | −11.3% |
| Q4 2023 | Feb 14, 2024 · Before open | −8.2% |
| Q3 2023 | Nov 8, 2023 · Before open | −1.3% |
| Q2 2023 | Aug 9, 2023 · After close | +2.9% |
| Q1 2023 | May 10, 2023 · Before open | −2.4% |
| Q4 2022 | Feb 8, 2023 · Before open | −12.8% |
| Q3 2022 | Nov 9, 2022 · Before open | −9.6% |
| Q2 2022 | Aug 10, 2022 · After close | −1.2% |
| Q1 2022 | May 11, 2022 · Before open | −2.8% |
| Q4 2021 | Feb 9, 2022 · Before open | +5.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 22 slides | August 2026 |
| Surgical Infection Society 45th Annual Meeting (SIS 2026) | Conference | 10 slides | May 2026 |
| Technical Presentation (June 2025) | Technical | 12 slides | Jun 9, 2025 |
| Corporate Update (June 2022) | Corporate update | 42 slides | June 2022 |
| Investor Presentation (July 2021) | Investor deck | 22 slides | Jul 2, 2021 |
| Technical Presentation (December 2020) | Technical | 39 slides | Dec 15, 2020 |
| IPO Roadshow (October 2014) | IPO roadshow | 34 slides | Oct 31, 2014 |
Financings
| Raise | Date |
|---|---|
| Warrant exercise of ordinary shares on exercise of existing warrants Closed: US$26.7M raised · US$3.5 a share · Warrants at US$4.5 for 24 months Use of proceeds: NDA submission, launch preparations, working capital and general corporate purposes | Aug 13, 2025 |
| Private placement of securities with warrants Closed: US$14.5M raised · US$3.22 a share · Warrants at US$4 · Citizens JMP Dealers: Citizens JMP (lead) Buyers: AIGH (lead investor) Use of proceeds: Extend cash runway into the third quarter of 2025, beyond expected SHIELD II top-line results | Feb 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Jun 25, 2020.
- Price
- US$16.00 a share
- Shares offered
- 3,750,000 ordinary shares
- Offering size
- US$60 million
- Underwriters' option
- Up to 562,500 more shares
- Listing
- PYPD on the Nasdaq Global Market
- Underwriters
- Barclays, BMO Capital Markets, Raymond James, National Securities Corporation, ODDO BHF, A.G.P. · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 24, 2020 |
| Filed publicly | Jun 5, 2020 |
| Amended twice | Newest Jun 22, 2020 |
| Shares registered with an exchange | Jun 18, 2020 |
| Declared effective by the SEC | Jun 25, 2020 |
| Final prospectus, with the price | Jun 29, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 29, 2020 |
| EFFECT · Notice that a registration is effective | Jun 25, 2020 |
| F-1MEF · Registration of more shares for the same offering | Jun 25, 2020 |
| CERT · Exchange's certificate of listing | Jun 24, 2020 |
| CORRESP · Letter to the SEC | Jun 23, 2020 |
| CORRESP · Letter to the SEC | Jun 23, 2020 |
| CORRESP · Letter to the SEC | Jun 22, 2020 |
| F-1/A · Registration statement, amended | Jun 22, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 18, 2020 |
| UPLOAD · Letter from the SEC | Jun 17, 2020 |
All 18 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 15, 2020 |
| F-1/A · Registration statement, amended | Jun 15, 2020 |
| UPLOAD · Letter from the SEC | Jun 9, 2020 |
| CORRESP · Letter to the SEC | Jun 5, 2020 |
| F-1 · Registration statement | Jun 5, 2020 |
| DRSLTR · Letter to the SEC with a draft | Apr 14, 2020 |
| UPLOAD · Letter from the SEC | Mar 19, 2020 |
| DRS · Draft registration statement | Feb 24, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 29, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.62M | 1.82M | 1.72M | 1.12M | 1.01M | 947.0K | 411.0K | 205.0K | 127.0K | |
| Gross profit | -1.62M | -1.82M | -1.72M | -1.12M | -1.01M | -947.0K | -411.0K | -205.0K | -127.0K | |
| Research and development | 23.8M | 22.8M | 16.1M | 28.0M | 30.6M | 17.0M | 14.1M | 12.6M | 9.74M | 7.71M |
| Selling, general and administrative | 7.18M | 4.27M | 5.52M | 8.01M | 9.48M | 7.70M | 4.48M | 5.26M | 4.06M | 2.55M |
| Operating income | -33.0M | -28.0M | -22.9M | -38.9M | -43.1M | -26.3M | -18.6M | -18.4M | -13.8M | -10.3M |
| Depreciation and amortization | 1.46M | 1.62M | 1.82M | 1.72M | 1.12M | 1.01M | 947.0K | 411.0K | 205.0K | 127.0K |
| EBITDA | -31.5M | -26.4M | -21.0M | -37.2M | -42.0M | -25.3M | -17.6M | -18.0M | -13.6M | -10.1M |
| Interest expense | 685.0K | 1.52M | 1.71M | 1.02M | 87.1M | 17.0K | 15.0K | 42.0K | 16.0K | 108.0K |
| Income before tax | -34.2M | -29.0M | -23.8M | -39.4M | -42.6M | 36.9M | -6.91M | 5.92M | -54.5M | -11.4M |
| Income tax | 5.00K | 42.0K | 69.0K | 129.0K | -1.62M | -1.54M | -11.7M | -24.3M | 40.7M | 1.13M |
| Net income | -34.2M | -29.0M | -23.9M | -39.6M | -42.6M | -36.9M | -6.91M | 5.92M | -54.5M | -11.4M |
| Earnings per share, basic | 2.09 | 4.91 | 16.99 | 61.09 | 68.27 | 4.48 | 23.69 | -0.16 | -92.64 | -19.37 |
| Earnings per share, diluted | 2.09 | 4.91 | 16.93 | 61.09 | 68.27 | 4.48 | 23.69 | 0.86 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 6.40M | 15.6M | 5.31M | 8.55M | 9.82M | 4.32M | 3.92M | 7.77M | 3.91M | 10.2M |
| Short-term investments | 6.53M | 0 | 0 | 4.04M | 22.4M | 40.2M | 22.7M | 0 | 14.0M | 7.53M |
| Receivables | 298.0K | 118.0K | 139.0K | 18.0K | 24.0K | 28.0K | 28.0K | |||
| Inventory | 1.11M | 0 | 213.0K | -118.0K | 646.0K | 351.0K | -24.0K | |||
| Current assets | 15.2M | 16.6M | 6.07M | 14.2M | 34.8M | 47.2M | 27.4M | 8.03M | 18.7M | 18.3M |
| Property, plant and equipment | 5.09M | 6.08M | 7.62M | 9.25M | 8.76M | 5.89M | 6.12M | 6.19M | 2.93M | 847.0K |
| Total assets | 22.3M | 25.2M | 15.4M | 26.0M | 44.2M | 75.8M | 33.8M | 14.5M | 23.0M | 19.2M |
| Accounts payable | 2.86M | 2.41M | 772.0K | 1.14M | 4.14M | 974.0K | 1.58M | 1.13M | 2.02M | 778.0K |
| Current liabilities | 7.74M | 12.7M | 7.29M | 8.55M | 8.08M | 2.88M | 2.58M | 3.69M | 3.36M | 1.70M |
| Long-term debt | 634.0K | 6.38M | 7.57M | 47.4M | 6.62M | |||||
| Total debt | 988.0K | 7.42M | 10.4M | 11.6M | ||||||
| Total liabilities | 11.3M | 17.5M | 17.5M | 20.1M | 8.28M | 3.07M | 2.83M | 96.2M | 111.6M | 53.2M |
| Shareholders' equity | 11.0M | 7.68M | -2.10M | 5.83M | 36.0M | 72.8M | -87.6M | -81.7M | -88.6M | -34.0M |
| Shares outstanding | 18.2M | 10.2M | 1.65M | 669.6K | 18.8M | 18.5M | 562.7K | 18.8M | 588.1K | 588.1K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -27.9M | -22.0M | -17.2M | -34.3M | -32.4M | -21.6M | -17.4M | -16.7M | -12.3M | -9.73M |
| Capital spending | -210.0K | -76.0K | -196.0K | -1.77M | -2.65M | -781.0K | -879.0K | -3.07M | -1.88M | -539.0K |
| Free cash flow | -28.1M | -22.0M | -17.4M | -36.1M | -35.0M | -22.4M | -18.2M | -19.8M | -14.2M | -10.3M |
| Cash from investing | -6.70M | -330.0K | 3.80M | 16.6M | 36.9M | -40.8M | -23.6M | 11.0M | -8.38M | -8.07M |
| Cash from financing | 25.4M | 32.4M | 9.98M | 16.4M | 1.03M | 62.8M | 37.7M | 9.39M | 14.4M | 26.3M |
| Share buybacks | 37.7M | 9.39M | 14.4M | 26.3M | ||||||
| Change in cash | -9.21M | 10.1M | -3.46M | -1.31M | 5.55M | 410.0K | -3.27M | 3.67M | -6.31M | 8.54M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 28, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 1, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 1, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Aug 12, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 12, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Aug 12, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 256 filings. Open Filings
Cap table
Built by 6ix from PolyPid Ltd.’s releases · as of Sep 30, 2026
- Common shares
- 20,311,766
- Fully diluted
- 20,311,766
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 20,311,766 | Sep 30, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$4.50 · expire about Jun 2027 |
| Warrants · US$4.00 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 20,311,766 |
| Sep 30, 2026 | 21,125,704 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brooke Story Other companies: LivaNova PLC (Director since 2022 · Since at least Sep 15, 2022); Sigilon Therapeutics Inc (Director · Jun 14, 2021 – May 26, 2022 · Past) | Chairman of the Board · Since at least Dec 16, 2025 |
| Robert Benjamin Stein Other companies: Protagenic Therapeutics, Inc. (Director · Mar 25, 2024 – Mar 25, 2024 · Past) | Director · Since at least Mar 18, 2026 |
| Dalit Fellous Hazan | Deputy CEO, EVP, RD, CRA · Since at least Mar 18, 2026 |
| Dikla Czaczkes Akselbrad | Chief Executive Officer · Since at least Mar 18, 2026 |
| Itzhak Krinsky | Director · Since at least Mar 18, 2026 |
| Jonathan Missulawin | Chief Financial Officer · Since at least Mar 18, 2026 |
| Joseph BenAmram | Director · Since at least Mar 18, 2026 |
| Nir Dror-Darwish | Director · Since at least Mar 18, 2026 |
| Nurit Tweezer-Zaks | Chief Medical Officer · Aug 12, 2025 – Nov 5, 2026 · Past |
| Ori Warshavsky | PolyPid Investor Relations and Media Contacts · Since at least Mar 18, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Yechezkel Barenholz | Director · Since at least Mar 18, 2026 |
| Yitzchak Shlomo Jacobovitz | Director · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about PolyPid Ltd.